期刊文献+

结核分枝杆菌喹诺酮类耐药基因研究进展 被引量:3

Advances on target gene mutation in quinolones-resistance mycobacterium tuberculosis
下载PDF
导出
摘要 日益增多的耐喹诺酮类结核分枝杆菌给结核病疫情的控制带来了巨大挑战,深入研究结核分枝杆菌喹诺酮类耐受机制便成为应对挑战的关键。药物靶基因突变是导致结核分枝杆菌喹诺酮类耐受的主要因素,近年来该方面的研究逐步受到重视并取得了一些进展,本文特对此进行述评。 A challenge for TB control is an increasing number of quinolones-resistant mycobactertum tu- berculosis. It is necessary for us to further investigate the mechanism of quinolones-resistance in mycobacteri-um tuberculosis. Mutation in target gene is the primary cause resulting in quniolones-resistance and attracts more attention in recent years. So we are going to review some new findings on this topic and give readers some advices for in-depth research.
作者 王前 郑磊
出处 《实验与检验医学》 CAS 2012年第2期103-106,共4页 Experimental and Laboratory Medicine
基金 广东省教育部产学研结合项目(2009B090300281) 广东省科技计划项目重点项目(2010A030300006)
关键词 结核分枝杆菌 喹诺酮类耐受 药物靶基因突变 Mycobacterium tuberculosis Quinolones-resistance Mutation in target gene
  • 相关文献

参考文献42

  • 1World Health Organization. Global tuberculosis control 2009: epi- demiology strategy financing[M]. Geneva: WHO Press, 2009:6-15.
  • 2Cohen T, Colijn C, Wright A, et al. Challenges in estimating the total burden of drug-resistant tuberculosis [J]. Am J Respir Crit Care Med, 2008,177(12):1302-1308.
  • 3Feuerriegel S, Cox HS, Zarkua N, et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tu- berculosis strains in multidrug-resistant tuberculosis patients un- dergoing treatment [J]. Antimicrob Agents Chemother, 2009,53(8): 3353-3356.
  • 4Hooper DC. Mechanisms of action and resistance of older and new- er fluoroquinoloues[J]. Clin Infect Dis, 2000,31 Suppl 2:S24-28.
  • 5Andersson MI, MacGowan AP. Development of the quinolones[J]. J of Antimicrob Chemother, 2003,51 Suppl 1:1-11.
  • 6Emmerson AM, Jones A M. The quinolones: decades of develop- ment and use[J]. J Antimicrob Chemother, 2003,51 Suppl 1:13-20.
  • 7Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal ac- tivity of ciprofloxacin in patients with pulmonary tuberculosis [J]. Am J Respir Crit Care Med, 1997,156(3 Pt 1):901-905.
  • 8Vacher S, Pellegrin JL, Leblanc F, et al. Comparative antimycobac- terial activities of ofloxacin, ciprofloxacin and grepafloxacin [J]. J Antimicrob Chemother, 1999,44(5):847-852.
  • 9Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best pre- dict in vivo efficacy[J]. Antimicrob Agents Chemother, 2007,51 (2): 576-582.
  • 10Akcali S, Surucuoglu S, Cicek C, et al. In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tu- berculosis[J]. Ann Saudi Med, 2005,25(5):409-412.

二级参考文献31

  • 1结核病诊断细菌学检验规程[J].中国防痨杂志,1996,18(1):28-31. 被引量:799
  • 2Jarlier V, Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei [J ]. J Bacteriol, 1990,172:1418.
  • 3Takiff H E, Cimino M, Musso M C. et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis [J].Proc Natl Acad Sci USA. 1996.93 : 362.
  • 4Yew W W. Chan C K, Leang C C. et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong [J]. Chest, 2003,124(4): 1476.
  • 5Alangaden G J, Lerner S A. The clinical use of flouroquinolones for the treatment of Mycobacterial diseases[J]. Clin Infect Dis, 19 9 7 , 2 5 : 1213.
  • 6Richeldi L, Covi I. Ferrara G, et al. Clinical use of levofloxacin in the long-term treatment of drug resistant tuberculosis [J]. Monaldi Arch Chest Dis, 2002,57 ( 1 ) : 39.
  • 7Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations [J]. Antimicrob Agents Chemother, 1994, 38(4):773.
  • 8Alangaden G J, Manavathu E K, Vakulenko S B, et al.Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients [J]. Antimicrob Agents Chemother, 1995,39 (8) : 1700.
  • 9Guillemin I, Cambau E, Jarlier V. Sequences of conserved region in the a subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis an dimplication for intrinsic susceptibility to quinolones [J].Antimicrob Agents Chemother , 1995,39 (9):2145.
  • 10Kocagoz T, Hackbarth C J, Unsal I, et al. Gyrase mutations in laboratory-selected, fluoroquinolone- resistance,mutants of Mycobacterium tuberculosis H37Ra [J ].Antimicrob Agents Chemother , 1996,40(8) : 1768.

共引文献10

同被引文献17

  • 1梅建,薛桢,沈鑫,沈国妙,桂晓红,沈梅,高谦.原发性耐药是耐药结核病产生的重要原因[J].中华结核和呼吸杂志,2006,29(2):75-78. 被引量:103
  • 2FingraDC, Richardson CJ, Tee AR, et a.l mTOR controls cell cycleprogression through its cell growth effectors S6K1 and 4E2BP1 /eukaryotic translation initiation factor 4E [J]. Mol Cell Biol,2004,24(1): 200-216.
  • 3MicKinneyJD, Sacchettini JC, et al. Persistence of mycobacteriumtuberculosis in macrophages and mice requires the glyoxylateshunt enzyme isocitrate lyase[J]. Nature,2000, 406(6797):735-738.
  • 4AltmanJK’Yoon P,Katsoulidis E,et al. Regulatory effects of mam-malian target of rapamycin -mediated signals in the generation ofarsenic trioxide responses [J].J Biol Chem, 2008,283 (4) : 1992-2001.
  • 5SinnbergT, Lasithiotakis K,Niessner H,et al. Inhibition of PI3K-AKT -mTOR signaling sensitizes melanoma cells to cisplatin andtemozolomide[J]. J Invest Dermatol, 2009,129(6): 1500-1515.
  • 6FlotoRA, Sarkar S, Perlstein EO, et al. Small molecule enhancersof rapamycin -induced TOR inhibition promote autophagy, reducetoxicity in Huntington’s disease models and enhance killing ofmycobacteria by macrophages[J]. Autophagy,2007, 3(6), 620-622.
  • 7VergneI,Singh S, Roberts E,et al.Autophagy in immune defenseagainst mycobacterium tuberculosis[J]. Autophagy,2006, 2(3),175-178.
  • 8FireA, Xu S, Montgomery MK, et al. Potent and specific geneticinterference by double - stranded RNA in Caenorhabditis elegans[J]. Nature,1998; 391(6669):806-811.
  • 9胡冬华,欧阳福桂,李鹰,李琴,王祖康,刘琼.耐多药结核杆菌对二线抗结核药物的敏感性实验研究[J].实验与检验医学,2010,28(6):543-545. 被引量:6
  • 10钟球,尹建军,钱明,周琳,陈涛,李建伟,黄桂清,蒋莉.广东省第五次结核病流行病学抽样调查分析[J].中国防痨杂志,2011,33(6):317-322. 被引量:64

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部